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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
ceramide containing creams are a safe and effective treatment for patients with atopic dermatitis.
STUDY DESIGN: Review of three randomized controlled studies published in English between
2009-2016.
DATA SOURCES: Three assessor blind randomized controlled trials found using PubMed and
EbscoHOST databases.
OUTCOMES MEASURED: Each of the three trials assessed safety and efficacy of a ceramide
containing cream compared with another method in the treatment of atopic dermatitis. Outcomes
were measured by Eczema Severity Score (ESS), rating of skin dryness on a 0-4 scale,
transepidermal water loss (TEWL) measurements, and Severity Scoring for Atopic Dermatitis
(SCORAD) on a scale of 0-72.
RESULTS: The Marseglia et al1 study showed that subjects using the ceramide containing cream
had an 84% reduction in their Eczema Severity Score (ESS), compared to the subjects using the
simple hydrating cream who had a 50% reduction in the ESS. This difference was statistically
significant as p=0.0001. The Simpson et al2 study showed statistically significant improvements
in skin dryness, skin hydration and transepidermal water loss (TEWL) in the cream with a
ceramide precursor as compared to no treatment. The Sugarman et al3 study showed a 50.7%
decrease (p<0.001) in Severity Scoring for Atopic Dermatitis (SCORAD) when using a ceramide
formulation. Additionally, it showed no statistically significant difference between the SCORAD
in the ceramide formulation and fluticasone propionate 0.05%. No serious adverse effects were
noted in the three studies.
CONCLUSIONS: The results of the three randomized controlled studies show that the use of a
ceramide containing cream is a safe and effective treatment for atopic dermatitis. Each study
showed a statistically significant improvement of symptoms without any serious adverse effects.
KEY WORDS: Atopic dermatitis, eczema, ceramide
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INTRODUCTION
Atopic dermatitis, or eczema, is a chronic pruritic inflammatory skin disease. It is
characterized by epidermal changes including spongiosis, acanthosis, hyperkeratosis, and
lymphhistiocytic infiltrate into the dermis.4 Two cardinal symptoms of atopic dermatitis are
pruritus and xerosis, but the presentation can vary depending on the patient and severity. 4 This
paper evaluates three randomized controlled trials (RCTs) comparing the efficacy of a ceramide
containing cream as the treatment for atopic dermatitis as compared with other treatment options.
Atopic dermatitis is relevant to the Physician Assistant due to the prevalence and cost of
the disease. Atopic dermatitis effects on average 5% to 20% of children worldwide, and
approximately 11% of children located in the U.S. Most cases of atopic dermatitis present prior
to the age of five years old, and there is a female to male ratio of 1.3 to 1. The incidence of
atopic dermatitis is increasing.4 JAMA Dermatology estimated that adults with eczema had $371
to $489 higher out-of-pocket costs per person-year compared to those without eczema.6 They
paid $37 billion and $29 billion in out-of-pocket health care costs in 2010 and 2012,
respectively.6 Not only are monetary costs of the disease higher; but patients with atopic
dermatitis are physically visiting their physician more often. In the 2010 National Health
Interview Survey (NHIS), approximately three of four adults with eczema (six million) had seen
a physician for their eczema in the previous 12 months.6 In addition, adults with eczema had a
weighted total of 9.7 million (for 2010) and 7.8 million (for 2012) visits to an urgent care center
or emergency department in the previous 12 months. 6
The etiology of atopic dermatitis is multifactorial including skin barrier abnormalities,
defects in innate or adaptive immunity response, and altered skin resident microbial flora. 4
Impaired skin barrier function of intercellular junctions or the stratum corneum, such as

Francis, Atopic Dermatitis and Ceramides

2

deficiency in stratum corneum lipids (ceramides), can lead to increased transepidermal water loss
(TEWL).4 Increase in TEWL can lead to dryness and severe pruritus, which are the cardinal
symptoms of atopic dermatitis. Patient presentations of atopic dermatitis can vary based on how
long symptoms have been present. Acute symptoms include pruritic erythematous papules and
vesicles which may include crusting or weeping lesions. Chronic atopic dermatitis usually
presents with scales, excoriation, fissuring, and lichenification of skin. 4 Atopic dermatitis is
often associated with elevated serum level of IgE as well as a personal or family history of atopy
(atopic dermatitis, asthma, and allergic rhinitis).4
Treatment of atopic dermatitis includes a multipronged approach including elimination of
exacerbating factors, restoration of skin barrier function, hydration of the skin, and
pharmacologic treatment of skin inflammation.5 Many patients with atopic dermatitis have a
deficiency in stratum corneum lipids (ceramides), so maintaining skin hydration with thick
cream, ointment, or moisturizers containing stratum corneum lipids is a key component.5 Lotions
that have a high water and low oil content can worsen xerosis, where thicker creams (such as
Eucerin, Cetaphil, Nutraderm) and ointments (such as petroleum jelly, Vaseline, Aquaphor) have
lower to no water content and can better protect against xerosis.5 Symptoms of pruritus can be
treated and controlled with antihistamines. Other pharmacologic treatments include topical
corticosteroids. Typically, low potency for mild symptoms and medium to high potency for
moderate to severe symptoms. Acute exacerbations may even require a short course of systemic
glucocorticoids. 5
The goal of the proposed treatment method is to have a safe and effective role in treating
atopic dermatitis and reduce the severity of symptoms. This review compares a ceramide
containing cream with three different treatment options: no treatment, a non-ceramide containing

Francis, Atopic Dermatitis and Ceramides

3

cream, and a topical corticosteroid. The goal of using a ceramide containing cream is to replace
the deficiency of stratum corneum lipids and potentially reduce or eliminate the need for topical
or systemic corticosteroid use. The use of ceramide cream has been shown to be a safe and
effective treatment of atopic dermatitis in those six months to 65 years old.

OBJECTIVE
The objective of this selective EBM review is to determine whether or not ceramide
containing creams are a safe and effective treatment for patients with atopic dermatitis.

METHODS
The three studies in this review were randomized controlled trials that met the following
criteria: the population studied were men and women ages six months to 65 years with atopic
dermatitis. Interventions included a ceramide containing cream, a moisturizer with ceramide
precursor, and a ceramide-dominant triple-lipid barrier repair formulation. Comparisons were
made to a non-ceramide simple hydrating cream, no intervention, and a steroid containing cream
(fluticasone propionate 0.05% cream). The outcomes measured were decrease in atopic
dermatitis severity (measured by Eczema Severity Scoring and Severity Scoring for Atopic
Dermatitis), reduction in skin dryness, and improvement in skin barrier function via reduction in
trans epidermal water loss (TEWL). 1,2,3
Keywords used to search for articles consisted of: ceramide, atopic dermatitis, and
eczema. All articles were published in English in peer-reviewed journals. Articles were
researched by the author via PubMed and EbscoHOST and selected based on relevance to the
clinical question that included patient oriented outcomes (POEMs). Inclusion criteria included
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RCTs published after 2000, men and women aged six months to 65 years with atopic dermatitis,
and patient oriented evidence that matters (POEMs). Exclusion criteria included articles
published prior to 2000 and studies focused on disease oriented evidence (DOEs). Statistics
reported and used include: p-value, relative benefit increase (RBI), absolute benefit increase
(ABI), control event rate (CER), experimental event rate (EER) and numbers needed to treat
(NNT). Table 1 displays demographics and characteristics of included studies.

OUTCOMES MEASURED
All outcomes measured included patient oriented outcomes in the reduction of atopic
dermatitis symptom severity. The Marseglia et al1 study examined the reduction in eczema
severity using the Eczema Severity Score (ESS) by blind evaluators clinical observations of
erythema, induration, edema and lichenification on a 0-3 scale. The Simpson et al2 study
examined a reduction in skin dryness and improvement in skin barrier function using blind
evaluators to rate skin dryness on a 0-4 scale and take TEWL measurements at baseline and day
28. The Sugarman et al3 study examined a decrease in eczema severity using the Severity
Scoring for Atopic Dermatitis (SCORAD) on a scale of 0-72.

Francis, Atopic Dermatitis and Ceramides
Table 1. Demographics and characteristics of included studies
Study
Type
#of Age
Inclusion
Exclusion
Pts (yrs)
Criteria
Criteria
Marseglia, Assessor
107 6
Children aged Severe
2014 [1]
blind RCT
months 6 months to
recent atopic
to 14
14 years with eczema (<4
years
facial atopic
weeks), and
eczema
treatment
with
systemic or
topical
steroids or
calcineurin
inhibitors,
and presence
of active
cutaneous
bacterial,
viral, or
fungal
infections in
target areas
Simpson, Blind
20 18
Men and
Pregnant or
2013 [2]
evaluator
years
women ages
breast
RCT
to 65
18-65 with
feeding
years
controlled
women
atopic
dermatitis,
patients also
have clinical
xerotic skin,
corresponding
to a score of
at least 1 on a
dryness scale
Sugarman, Investigator 121 6
Male and
None listed
2009 [3]
blind
months female
comparison
to 18
patients ages
controlled
years
6 months to
RCT
18 years old
with
moderate-tosevere atopic
dermatitis

W/D Interventions
0

A ceramide
containing
cream
(Nutratopic
Pro-AMP
cream),
which also
contains
2.5%
rhamnosoft
and 2% Lisoleucine
(ILE)

0

Moisturizer
with
ceramide
precursor
(Cetaphil
Restoraderm
Body
Moisturizer)
applied
twice daily
on one leg
for 27 days

5
Ceramide(4%) dominant,
triple-lipid,
barrierrepair
formulation
(EpiCream
Skin Barrier
Emulsion)

5
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RESULTS
All three articles studied the use of a ceramide containing cream as a safe and effective
treatment for atopic dermatitis. The Marseglia et al1 study compared a ceramide containing
cream to no intervention, the Simpson et al2 study compared to a non-ceramide containing
cream, and the Sugarman et al3 study compared with a topical corticosteroid.
The Marseglia et al1 study examined 107 children aged six months to 14 years with facial
atopic eczema and excluded children with severe recent atopic eczema, treatment with systemic
or topical corticosteroids, and presence of active cutaneous infections at target lesions. Subjects
were randomly assigned to one of two groups, and either applied a ceramide containing cream
(Nutratopic Pro-AMP cream) or a simple hydrating cream (15% glycerol-based cream containing
Vaseline 8% and liquid paraffin 2%). Subjects applied the topical treatments to the face two
times a day for six weeks. Blind evaluators determined subject’s Eczema Severity Score (ESS) at
baseline, three weeks, and then six weeks. ESS is calculated based on clinical observation of
erythema, induration, edema, and lichenification of skin. Table 2 displays the ESS at baseline,
week three and week six. The baseline ESS score for the ceramide containing cream, mean +/standard deviation (SD), was 6.1 +/- 2.5 versus 5.3 +/- 3.0 for the comparison group. At week 6
the ESS for the ceramide containing cream was 1.0 +/- 1.5, demonstrating an 84% reduction,
p=0.0001. The comparison group ESS at week 6 was 2.6 +/- 2.0, showing a 50% reduction. The
ESS mean change from baseline at week 6 was -5.0 points and -2.7 points for the treatment
group and comparison group respectively. The ESS in the treatment group at week 6 was
significantly lower than the comparison group (1.0 vs 2.6, CI 95%).1
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Table 2. Change in ESS for Marseglia et al1 study
Treatment
Baseline ESS
Week 3 ESS
(Mean +/- SD) Mean +/- SD
% reduction
Ceramide
6.1 +/- 2.5
2.5 +/- 2.0
containing cream
59% reduction
Simple hydrating
5.3 +/- 3.0
3 + 2.0
cream
42% reduction

Week 6 ESS
Mean +/- SD
% reduction
1.0 +/- 1.5
84% reduction
2.6 +/- 2.0
50% reduction

7

Absolute
reduction
(CI 95%)
5.0 points
(CI: 5.5 to 4.5)
2.7 points
(CI: 3.6 to 1.4)

The Simpson et al2 study examined 20 men and women (excluding pregnant or
breastfeeding subjects) ages 18-65 with controlled atopic dermatitis and clinical xerotic skin.
Subjects were given a moisturizer with a ceramide precursor (Cetaphil Restoraderm Body
Moisturizer, or CRM) and applied it daily on one leg for 28 days. Each subject was also their
own control, as no treatment was done to the other leg. Blind evaluators assessed level of skin
dryness on a 0-4 scale, level of skin hydration, and TEWL measurements at baseline and 28 days
later. Table 3 displays the results. Percentage change in skin dryness from baseline is -55.54%
and -22.17% for treated area versus non-treated area, p-value <0.001. Percentage change in skin
hydration from baseline was +117.53% and +25.42% for treated area versus non-treated area
respectively, p-value <0.001. Percentage change in TEWL from baseline was -30.01% and
-4.28% for treated area versus non-treated area, p-value = 0.002.2
Table 3. Results for Simpson et al2 study
Treatment
% change in skin
dryness from
baseline
Moisturizer with
-55.54%
ceramide precursor
No treatment
-22.17%
p-value
p<0.001

% change in skin
hydration from
baseline
+117.53%

% change in
TEWL from
baseline
-30.01%

+25.42%
p<0.001

-4.28%
p=0.002

The Sugarman et al3 study examined 121 male and female patients ages six months to 18
years with moderate to severe atopic dermatitis. Subjects were randomly placed into two
treatment groups. One group was treated with a ceramide-dominant, triple-lipid, barrier-repair
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formulation (EpiCream Skin Barrier Emulsion), and the other group was treated with Fluticasone
proprionate 0.05% cream. Subjects applied the cream to affected areas at approximately the same
time every day for 28 days. Blind evaluators assessed atopic dermatitis severity using the
Severity Scoring for Atopic Dermatitis (SCORAD) on a scale of 0-72 at baseline, day 14, and
day 28. Table 4 displays the percent change from baseline in SCORAD on day 14 and day 28 as
well as an analysis of variance (ANOVA) comparison. SCORAD mean change from baseline at
14 days was -36.6% and -50.7% for the ceramide barrier cream and the fluticasone cream groups
respectively. SCORAD mean change from baseline at 28 days was -50.7% and -66.7% for
ceramide barrier cream and the fluticasone cream groups respectively. When comparing the
change in baseline from the ceramide group to the fluticasone group, the ANOVA p-value was
0.134. This reveals there is not a statistically significant difference in the outcome between the
two treatment groups, suggesting the ceramide containing cream would be a safe and effective
treatment option that could replace fluticasone cream use. When looking solely at the ceramide
group change from baseline, the -50.7% change is statistically significant as p<0.001.3
Table 4. Results for Sugarman et al3 study
Treatment
% change in SCORAD
from baseline at day 14
Ceramide formulation
-36.6%
Fluticasone proprionate 0.05% -57.6%
ANOVA p-value
p=0.021

% change in SCORAD
from baseline at day 28
-50.7%
-66.7%
p=0.134

Sugarman et al3 data was converted to dichotomous; see Tables 5 and 6. Subjects who
had >75% improvement in SCORAD where considered to have “excellent responses.” At day 14
the ceramide barrier cream group had five subjects and the fluticasone cream group had 21
subjects with “excellent responses”. At day 28 the ceramide barrier cream group had 21 subjects
with “excellent responses” and the fluticasone cream group had 27 subjects. Table 6 shows
calculations for RBI, ABI, EER, CER, and NNT. NNT was determined to be -14. This means for
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every 14 people treated with the ceramide cream, one less subject will obtain an “excellent
response” compared to the fluticasone cream.3
Table 5. Dichotomous data for Sugarman et al3 study
Treatment
# people with >75%
improvement in SCORAD
on day 14
Ceramide formulation
5
Fluticasone proprionate 0.05% 21

# people with >75%
improvement in SCORAD
on day 28
21
27

Table 6. Values for dichotomous data for Sugarman et al3 study
CER
EER
RBI
ABI
0.46
0.39
1.84
-0.07

NNT
-14

DISCUSSION
Ceramides are stratum corneum lipids that aid in maintaining skin hydration.5 There are
no contraindications or black box warnings for the use of ceramides. 9 The Cosmetic Ingredient
Review (CIR) Expert Panel8 reviewed the safety of 23 forms of ceramides and concluded that,
“the following ceramide ingredients are safe in cosmetics in the present practices of use and
concentration described in this safety assessment.”8 An article in the Journal of Food and
Chemical Toxicology further expanded on the CIR Expert Panel conclusions and discovered,
“there may be sufficient margin of safety for systemic toxicity to humans if ceramide 3 is used
less than 1% as an ingredient for cosmetic products.”7
The Marseglia et al1 and Simpson et al2 studies did not display any adverse effects from
the use of ceramide cream. In the Sugarman et al3 study, while there were no serious adverse
events attributed to the agents studied, there were four subjects in the ceramide formulation
group who initially worsened and required “rescue therapy” with fluticasone use. The adverse
effects mimicked the subject’s original disease (atopic dermatitis), so the authors did not attribute
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the initial increase in severity of symptoms as directly caused by the ceramide formulation, but
rather as “disease flares”.3
Limitations to the Marseglia et al1 study and the Simpson et al2 study include that it was
not double blinded. The subjects in the Marseglia et al1 study could tell which cream (ceramide
containing or basic glycerol based) they were using. The subjects in the Simpson et al2 study
where their own control as they applied cream to one leg and not the other. In both studies this
was corrected for by having blind assessors evaluate the patients. Limitations to the Sugarman et
al3 study include that the subjects were not blinded, there was no placebo group, hydrocortisone
was substituted for some subjects, and five patients dropped out of the study. The subjects could
not be blinded as many had used fluticasone cream 0.05% before and knew the consistency.
There was no placebo group because the investigators deemed it unethical not to treat pediatric
patients with moderate to severe atopic dermatitis, so no subjects were left without treatment.
The investigators also substituted hydrocortisone cream 2.5% for the fluticasone cream 0.05% if
patients needed to use it on their face or intertriginous areas. Lastly, five patients either dropped
out of the study or were lost to follow up.

CONCLUSION
The results of the three randomized controlled trials in this selective EBM review
conclude that ceramide containing creams are a safe and effective treatment for atopic dermatitis.
All three studies showed a statistically significant reduction in atopic dermatitis symptoms after
the use of a ceramide containing cream. Additionally, the Sugarman et al3 study showed there is
no statistical difference between the ceramide dominant barrier cream and the fluticasone
formula after 28 days of treatment of moderate-to-severe atopic dermatitis. This is advantageous
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for pediatric patients who should not use steroid creams long term on their face. The ceramide
cream can decrease the need for topical steroids. Future studies should examine combination
therapy of a ceramide cream with a steroid cream. This type of research could also analyze the
efficacy of ceramide creams being used for a longer duration as a maintenance or preventive
therapy. In conclusion, this systematic review shows that ceramide containing creams are a safe
and effective treatment for symptoms of atopic dermatitis.
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